Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 380

Sort by

Sort Order Select

Journal Articles

Targeting cereblon in AML

Steven Grant

Blood (2021) 137 (5): 584–586.

https://doi.org/10.1182/blood.2020009827

Published: 2021

Journal Articles

A master erythroid regulator gets its own GPS

Lily Jun-shen Huang, James J. Bieker

Blood (2020) 135 (25): 2209–2210.

https://doi.org/10.1182/blood.2020005882

Published: 2020

Journal Articles

Wdr26 regulates nuclear condensation in developing erythroblasts

Ru Zhen, Chingyee Moo, Zhenzhen Zhao, Mengying Chen, He Feng, Xiaojun Zheng, Liang Zhang, Jiahai Shi, Caiyong Chen

Blood (2020) 135 (3): 208–219.

https://doi.org/10.1182/blood.2019002165

Published: 2020

Includes: Supplemental data

Journal Articles

Targeted Protein Degradation of BTK As a Unique Therapeutic Approach for B Cell Malignancies

Blood (2019) 134 (Supplement_1): 3805.

https://doi.org/10.1182/blood-2019-129262

Published: 2019

Journal Articles

Small Molecule-Induced, Selective STAT3 Degradation Leads to Anti-Tumor Activity in STAT3-Dependent Heme Malignancies

Fred Csibi, Nan Ji, PhD, Bin Yang, Karen Yuan, Michele Mayo, Haojing Rong, PhD, Scott Rusin, Kirti Sharma, Christine Loh, PhD, Henry Li, PhD, Sharon Townson, Jesse Chen, PhD, Hari Kamadurai, PhD, Duncan Walker, PhD, Jared Gollob, PhD MD, Nello Mainolfi, PhD

Blood (2019) 134 (Supplement_1): 3803.

https://doi.org/10.1182/blood-2019-128981

Published: 2019

Journal Articles

Identification of Deubiquitinase OTUD1 As a Novel Player in Resistance of Multiple Myeloma to Bortezomib

Alexander Vdovin, Tomas Jelinek, MD, Matous Hrdinka, PhD, Juli R. Bago, PhD, Tereza Sevcikova, Roman Hajek, Prof, MD PhD, Michal Simicek, PhD

Blood (2019) 134 (Supplement_1): 5526.

https://doi.org/10.1182/blood-2019-127930

Published: 2019

Journal Articles

Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase Inhibition

Tamara K Moyo, MD PhD, Justin M. Watts, MD, Barry S. Skikne, MD, Jason H. Mendler, MD PhD, Virginia M. Klimek, MD, Sheau-Chiann Chen, PhD, Run Fan, PhD MS, Ingrid A Anderson, PhD, Andrew Sochacki, MD, Stephen A. Strickland, MD, Michael T Byrne, DO, Terrence J Bradley, MD, Gregory D Ayers, MS, Sanjay R Mohan, MD MSCI, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 4236.

https://doi.org/10.1182/blood-2019-130003

Published: 2019

Journal Articles

The Role of Protein Tyrosine Phosphatase PTP4A3 in T-Cell Acute Lymphoblastic Leukemia Progression

Min Wei, MSc, Jessica Blackburn, PhD

Blood (2019) 134 (Supplement_1): 2539.

https://doi.org/10.1182/blood-2019-126256

Published: 2019

Journal Articles

Characterization of Monoclonal Gammopathy of Undetermined Significance Progression to Multiple Myeloma through Meta-Analysis of GEO Data

Jihad Aljabban, MMSc, BA, David Chen, BS, Francesca Cottini, MD, Saad Syed, BS, Nabeal Aljabban, BS, Sharjeel Syed, BS, Tiffany Hughes, PhD, David Feldman, BS, Dexter Hadley, MD PhD, Don M. Benson, Jr., MD PhD

Blood (2019) 134 (Supplement_1): 4395.

https://doi.org/10.1182/blood-2019-129699

Published: 2019

Journal Articles

Neddylation Pathway Regulates Treg Differentiation and T Cell Function in Chronic Lymphocytic Leukemia (CLL) Ex Vivo and Murine In Vivo Studies

Scott R Best, BS, Vi Lam, Nur Bruss, BS, Taylor Hashiguchi Rowland, BS, Adam S. Kittai, MD, Tingting Liu, Allison J Berger, PhD, Alexey Danilov, MD PhD

Blood (2019) 134 (Supplement_1): 4313.

https://doi.org/10.1182/blood-2019-123600

Published: 2019

Journal Articles

RFWD2 Induces Cellular Proliferation and Proteasome Inhibitor Resistance By Mediating p27 Ubiqutinaiton in Multiple Myeloma

Ye Yang, PhD, Mengjie Guo, Chunyan Gu

Blood (2019) 134 (Supplement_1): 3068.

https://doi.org/10.1182/blood-2019-127888

Published: 2019

Journal Articles

Loss of METTL3 Mediated m6A RNA Modification Results in Double-Stranded RNA Induced Innate Immune Response and Hematopoietic Failure

Blood (2019) 134 (Supplement_1): 450.

https://doi.org/10.1182/blood-2019-130442

Published: 2019

Journal Articles

The Ubiquitin Ligase DTX2 Promotes Nuclear Export of RUNX1 and Inhibits RUNX1-Dependent Leukemogenesis

Taishi Yonezawa, MSc, Hirotaka Takahasi, PhD, Tatsuya Sawasaki, PhD, Toshio Kitamura, MD PhD, Susumu Goyama, MD PhD

Blood (2019) 134 (Supplement_1): 1252.

https://doi.org/10.1182/blood-2019-126264

Published: 2019

Journal Articles

Can Monosomy 7 be Targeted By Next Generation Cereblon-Modulating Agents?

Blood (2019) 134 (Supplement_1): 1270.

https://doi.org/10.1182/blood-2019-128967

Published: 2019

Journal Articles

SIX1 Transcription Factor Enhances Human Erythropoiesis Via GATA1

Michael Creed, MSc, Christian Eberly, Jevon Cutler, PhD, MinJung Kim, PhD, Akhilesh Pandey, MD PhD, Curt I Civin, MD, Tami J Kingsbury, PhD

Blood (2019) 134 (Supplement_1): 3503.

https://doi.org/10.1182/blood-2019-131203

Published: 2019

Journal Articles

TNF-α Confers Resistance of Myeloma Cells to IMiDs through TRAF2 Degradation

Jiye Liu, PhD, Teru Hideshima, MD PhD, Lijie Xing, MD, Kenneth Wen, BS, Yu-Tzu Tai, PhD, Yong Cang, PhD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 1809.

https://doi.org/10.1182/blood-2019-123141

Published: 2019

Journal Articles

Lenalidomide Induction and Maintenance Maximizes Outcome for Newly Diagnosed Transplant Eligible Myeloma Patients Irrespective of Risk Status: Long-Term Follow-up of the Myeloma XI Trial

Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, David Cairns, MSc, PhD, John R Jones, MD, Bhuvan Kishore, MB BS, MRCP, FRCPath, Mamta Garg, MD FRCP, FRCPath, Cathy Williams, MD MRCP, FRCPath, Kamaraj Karunanithi, MD FRCPath, Jindriska Lindsay, MD, MRCP, FRCPath, Nigel H. Russell, MD, Matthew Jenner, MBBS, MRCP, FRCPath, Gordon Cook, MB ChB, PhD FRCP(Glas), FRCPath, Mark T Drayson, MB ChB, PhD FRCPath, Roger G. Owen, MD, Walter M Gregory, PhD, Martin F. Kaiser, Faith E. Davies, MD, Gareth Morgan, MDPhDFRCP

Blood (2019) 134 (Supplement_1): 1910.

https://doi.org/10.1182/blood-2019-126160

Published: 2019

Journal Articles

Chemically Induced Degradation of MALT1 to Treat B-Cell Lymphomas

Lorena Fontan, PhD, John Hatcher, PhD, David Scott, Qi Qiao, Ilkay Us, Guangyan Du, Matthew Durant, Jimmy Wilson, Hao Wu, PhD, Nathanael Gray, Ari Melnick, MD

Blood (2019) 134 (Supplement_1): 2073.

https://doi.org/10.1182/blood-2019-130666

Published: 2019

Journal Articles

Exploiting the Zinc Finger Degrome Targeted By Lenalidomide to Engineer Reversible Off-Switch Degradable Chimeric Antigen Receptors

Max Jan, MD PhD, Ana Castano, MD, Amanda Walker, BA, Andrew A Guirguis, MD PhD, Jessica A Gasser, PhD, Amanda A Bouffard, Mikolaj Slabicki, PhD, Alexander Tepper, Daniel E Grinshpun, Taeyoon Kyung, PhD, Quinlan Sievers, MD PhD, Michael E Birnbaum, PhD, Marcela V Maus, MD PhD, Benjamin L. Ebert, MD PhD

Blood (2019) 134 (Supplement_1): 866.

https://doi.org/10.1182/blood-2019-124210

Published: 2019

Journal Articles

Innate Immune Signaling Suppresses Acute Leukemia By Modifying MYC Oncogenic Activity

Tomoya Muto, MD PhD, Maria Guillamot, PhD, Jing Fang, MD PhD, Luna Zea Redondo, MS, Kwangmin Choi, PhD, Yixiao Gong, MSc, Callum S Walker, MSc, Kathleen Hueneman, Lyndsey C Bolanos, BSc, Laura Barreyro, PhD, Lynn Lee, MD, Kenneth D Greis, PhD, Alireza Khodadadi-Jamayran, M.Sc., Amaia Lujambio, PhD, Scott W. Lowe, PhD, Iannis Aifantis, PhD, Daniel T. Starczynowski, PhD

Blood (2019) 134 (Supplement_1): 727.

https://doi.org/10.1182/blood-2019-121423

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Targeting cereblon in AML

A master erythroid regulator gets its own GPS

Wdr26 regulates nuclear condensation in developing erythroblasts

Targeted Protein Degradation of BTK As a Unique Therapeutic Approach for B Cell Malignancies

Small Molecule-Induced, Selective STAT3 Degradation Leads to Anti-Tumor Activity in STAT3-Dependent Heme Malignancies

Identification of Deubiquitinase OTUD1 As a Novel Player in Resistance of Multiple Myeloma to Bortezomib

Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase Inhibition

The Role of Protein Tyrosine Phosphatase PTP4A3 in T-Cell Acute Lymphoblastic Leukemia Progression

Characterization of Monoclonal Gammopathy of Undetermined Significance Progression to Multiple Myeloma through Meta-Analysis of GEO Data

Neddylation Pathway Regulates Treg Differentiation and T Cell Function in Chronic Lymphocytic Leukemia (CLL) Ex Vivo and Murine In Vivo Studies

RFWD2 Induces Cellular Proliferation and Proteasome Inhibitor Resistance By Mediating p27 Ubiqutinaiton in Multiple Myeloma

Loss of METTL3 Mediated m6A RNA Modification Results in Double-Stranded RNA Induced Innate Immune Response and Hematopoietic Failure

The Ubiquitin Ligase DTX2 Promotes Nuclear Export of RUNX1 and Inhibits RUNX1-Dependent Leukemogenesis

Can Monosomy 7 be Targeted By Next Generation Cereblon-Modulating Agents?

SIX1 Transcription Factor Enhances Human Erythropoiesis Via GATA1

TNF-α Confers Resistance of Myeloma Cells to IMiDs through TRAF2 Degradation

Lenalidomide Induction and Maintenance Maximizes Outcome for Newly Diagnosed Transplant Eligible Myeloma Patients Irrespective of Risk Status: Long-Term Follow-up of the Myeloma XI Trial

Chemically Induced Degradation of MALT1 to Treat B-Cell Lymphomas

Exploiting the Zinc Finger Degrome Targeted By Lenalidomide to Engineer Reversible Off-Switch Degradable Chimeric Antigen Receptors

Innate Immune Signaling Suppresses Acute Leukemia By Modifying MYC Oncogenic Activity

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only